Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Subscribe To Our Newsletter & Stay Updated
